Avadel CNS v. Jazz Pharmaceuticals: XYWAV & LUMRYZ Patent Dispute Settled
Avadel CNS Pharmaceuticals brought a patent infringement action against Jazz Pharmaceuticals in Delaware over two patents covering sodium oxybate formulations tied to XYWAV and LUMRYZ. The parties reached a settlement, and the case was dismissed with prejudice after 244 days — with each side bearing its own legal costs.
Oxybate rivalry ends at settlement: XYWAV vs. LUMRYZ IP clash resolved
Avadel CNS Pharmaceuticals, LLC filed suit against Jazz Pharmaceuticals, Inc. in the District of Delaware on 25 February 2025, asserting infringement of US12226388B2 and US12226389B2 — two patents covering sodium oxybate formulations. The dispute centred on Jazz’s XYWAV product and Avadel’s own LUMRYZ, which are competing treatments in the narcolepsy and sleep disorder market where both companies have waged prolonged intellectual property battles.
The action was resolved by a joint stipulation of dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) and/or 41(a)(2), filed by Jazz Pharmaceuticals, Inc., Jazz Pharmaceuticals Ireland Limited, Avadel CNS Pharmaceuticals LLC, Avadel Pharmaceuticals plc, and Flamel Ireland Limited. All claims and counterclaims were dismissed with prejudice, meaning neither party may re-litigate the same claims. Each side agreed to bear its own attorneys’ fees and costs, a structure typically consistent with a negotiated commercial settlement rather than a clear adjudicated winner.
Resolution within 244 days suggests the parties likely reached commercial accommodation relatively early, possibly informed by prior litigation history between these companies over the same product category. The precise financial or licensing terms of the underlying settlement agreement are not disclosed in the public record, and it is not known from available filings whether any cross-licensing, royalty, or market-access arrangement was part of the resolution.
Filing to Dismissed with Prejudice in 244 days
244 days from filing to dismissal with prejudice — relatively swift resolution for a pharmaceutical patent dispute
Dismissed with prejudice: what the stipulated settlement means for both parties
Rule 41 dismissal with prejudice: the case is closed for good
A dismissal with prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) or 41(a)(2) is a final adjudication on the merits by operation of law. Neither Avadel nor Jazz may refile these specific claims against each other on the same patents. The stipulated nature of this dismissal — signed by all named parties including the Irish entities — indicates a voluntary, negotiated resolution rather than a court-imposed outcome.
Final — no refiling permittedAvadel’s patents survive, but infringement claims are extinguished
US12226388B2 and US12226389B2 remain in force as issued patents — the dismissal does not invalidate them. However, Avadel has relinquished its right to pursue Jazz for past or ongoing infringement under these patents in this action. Whether the settlement includes a licence, covenant not to sue, or other commercial term that governs future conduct between the parties is not disclosed in the public record.
Patents intact; enforcement vs. Jazz resolvedJazz secures finality on XYWAV exposure — on undisclosed terms
Jazz Pharmaceuticals obtained dismissal with prejudice of all claims asserted against it, providing legal certainty that Avadel cannot revive these specific patent claims in future litigation. The inclusion of Jazz Pharmaceuticals Ireland Limited and Flamel Ireland Limited as named parties in the stipulation suggests the settlement scope extends across the full commercial and IP holding structure of both groups. Underlying commercial terms remain confidential.
Full finality across corporate groupOxybate IP rivalry: settlement suggests commercial coexistence
The sodium oxybate market — anchored by narcolepsy and idiopathic hypersomnia treatments — has been a sustained battleground between Jazz and Avadel. A with-prejudice settlement on these two patents, with each side bearing its own costs, is consistent with the parties choosing market coexistence over continued litigation risk. Competitors and payers should note that neither patent’s validity was publicly adjudicated, leaving Avadel’s IP position intact for enforcement against third parties.
Coexistence likely; third-party risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Avadel CNS Pharmaceuticals, LLC | Company | CNS pharmaceutical company — holder of US12226388B2 and US12226389B2 (sodium oxybate formulations, LUMRYZ)Search in Eureka ↗ |
| Defendant | Jazz Pharmaceuticals, Inc. | Company | Jazz Pharmaceuticals, Inc. — developer and marketer of XYWAV, a competing low-sodium oxybate therapySearch in Eureka ↗ |
| Plaintiff counsel | Adam R. Brausa | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Alex M. Grabowski | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daralyn J. Durie | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Herman H. Yue | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kelly Welsh | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kenneth G. Schuler | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kira A. Davis | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Manuela Burek | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Marc N. Zubick | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Ramya Sri Vallabhaneni | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Cameron Paul Clark | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeremy A. Tigan | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation is signed across the full corporate structure of both groups — including the Irish holding entities — which suggests the settlement agreement itself has cross-border commercial scope beyond a simple US litigation resolution. The with-prejudice character of the dismissal forecloses Avadel from asserting these two patents against Jazz in any future US action, but leaves validity and enforceability against other parties entirely uncontested. The cost-neutral structure neither signals a winning nor losing party from the public record alone.
US12226388B2 & US12226389B2 — sodium oxybate formulation patents
US12226388B2 and US12226389B2 relate to sodium oxybate — the active ingredient in oxybate-based therapies used to treat excessive daytime sleepiness and cataplexy in narcolepsy patients. Both patents were asserted by Avadel in connection with its LUMRYZ product, a once-nightly extended-release formulation. The patents’ application numbers (US18/758699 and US18/759364) suggest relatively recent filings, consistent with continuation or formulation-based prosecution strategies common in branded pharmaceutical portfolios.
Sodium oxybate patents occupy a commercially critical position: as the branded oxybate market faces generic pressure and competing formulations, IP rights over specific dosing regimens, release profiles, and salt compositions can define market exclusivity windows. Avadel’s decision to assert these patents against Jazz’s XYWAV — a low-sodium mixed-salt oxybate — reflects the competitive intensity of this narrow but high-value therapeutic space. Any company developing oxybate-adjacent or gamma-hydroxybutyrate-related formulations should assess these patents as part of FTO analysis.
Should you run an FTO analysis against US12226388B2 and US12226389B2?
Any pharmaceutical company, generic applicant, or biotech developing sodium oxybate, gamma-hydroxybutyrate, or extended-release oxybate formulations for sleep or CNS indications should evaluate these patents before advancing to IND or NDA stage. The settlement’s with-prejudice dismissal means Avadel’s enforcement rights against non-Jazz parties are completely unaffected — these patents remain active tools in Avadel’s hands.
PatSnap Eureka’s FTO Search Agent can map US12226388B2 and US12226389B2 claim scope against your compound, formulation, or dosing regimen, identify relevant prior art that was not raised in this action, and flag continuation applications in the same family that may extend coverage. R&D and regulatory teams can run structured FTO queries directly in Eureka to generate a risk-ranked landscape before committing to clinical development resources.
Run a freedom-to-operate analysis on US12226388B2 to assess your product’s exposure
Run FTO in Eureka →Similar sodium oxybate and CNS pharmaceutical patent cases in Delaware
Explore related pharmaceutical patent infringement actions involving sodium oxybate, oxybate formulations, and CNS drug IP disputes litigated in the Delaware District Court.
What this case signals for the sodium oxybate pharmaceutical IP landscape
The Avadel–Jazz settlement closes one front in a multiyear oxybate IP war — but leaves unresolved questions for market entrants and generic challengers.
With-prejudice settlement leaves Avadel’s patents fully enforceable against others
Because no court found US12226388B2 or US12226389B2 invalid or unenforceable, Avadel retains full enforcement rights against any third party — including potential generic or 505(b)(2) applicants — who may be developing competing sodium oxybate formulations. Any company in this space should treat these patents as live enforcement risk.
Speed of resolution suggests prior relationship or parallel deal drove settlement
244 days is unusually fast for a pharmaceutical patent infringement dispute in Delaware. Avadel and Jazz have a documented history of prior litigation over oxybate products, which likely meant both parties had already formed views on relative merits and exposure. IP teams monitoring this space should review any concurrent licensing or regulatory activity between these parties.
Avadel v Jazz — key questions answered
Avadel CNS Pharmaceuticals asserted US12226388B2 and US12226389B2, both relating to sodium oxybate formulations. These patents are connected to Avadel’s LUMRYZ product and were asserted against Jazz’s XYWAV therapy in the District of Delaware.
The case was resolved by a joint stipulation of dismissal with prejudice signed by all parties, including Jazz Pharmaceuticals Ireland Limited, Avadel Pharmaceuticals plc, and Flamel Ireland Limited. Each party agreed to bear its own attorneys’ fees and costs, consistent with a negotiated commercial settlement.
No. A dismissal with prejudice pursuant to a stipulated settlement does not adjudicate patent validity or enforceability. US12226388B2 and US12226389B2 remain in force as issued patents. Avadel retains full rights to assert these patents against third parties other than Jazz.
Flamel Ireland Limited is included as a named party in the dismissal stipulation, suggesting it forms part of Avadel’s corporate and IP holding structure for the relevant sodium oxybate patents. Its inclusion indicates the settlement may have cross-border or multi-entity scope, though the precise terms of the settlement agreement are not public.
The case was filed in the United States District Court for the District of Delaware and was assigned to Judge Gregory B. Williams. The case was filed on 25 February 2025 and closed on 27 October 2025, a duration of 244 days.
PatSnap Eureka searches patents and litigation data to answer instantly.